Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of cytokines in multiple myeloma: IL-1RN and IL-4 VNTR polymorphisms.

Cytokine - 1 May 2022

Serin Istemi, Oyaci Yasemin, Pehlivan Mustafa, Pehlivan Sacide

Abstract excerpt

INTRODUCTION: The IL-1 receptor antagonist (IL-1Ra or IL-1RN) is a member of the IL-1 superfamily that functions as a competitive antagonist of the cell surface IL-1 receptor, thereby regulating various immune and inflammatory responses related to IL-1. IL-1 induces tumor growth and metastasis, while IL-1RN inhibits the secretion of IL-1α and IL-6 in cancer cells. Interleukin-4 (IL-4) is a potent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interleukin-1
Share to Genetic Predisposition to Disease
Share to Interleukin 1 Receptor Antagonist Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-4

Share to Minisatellite Repeats

Share to Multiple Myeloma

Share to Polymorphism, Genetic

Share to Receptors, Interleukin-1

Source

Identifiers

PMID: 35272075
DOI: 10.1016/j.cyto.2022.155851

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of cytokines in multiple myeloma: IL-1RN and IL-4 VNTR polymorphisms.PMID 35272075Read ↗

Effect of interleukin-2 (IL-2) polymorphisms on multiple myeloma: IL-2RA rs2104286, IL-2 rs2069762 and rs2069763 polymorphisms.Semantic proximity Read ↗

Effect of Cytokine Genes in the Pathogenesis and on the Clinical Parameters for the Treatment of Multiple Myeloma.Semantic proximity Read ↗

Association of interleukin-1A, interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms with multiple myeloma.Semantic proximity Read ↗

Association of IL-6 Promoter and Receptor Polymorphisms with Multiple Myeloma Risk: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis.Semantic proximity Read ↗

The role of immune checkpoint inhibitors: Variable number of tandem repeat (VNTR) polymorphism in the second exon of the P-selectin glycoprotein ligand-1 (PSGL-1) gene polymorphism in multiple myeloma.Semantic proximity Read ↗

Interleukin-6 gene-174 G/C promoter polymorphism is not associated with multiple myeloma susceptibility: evidence from meta-analysis: A systematic review and meta-analysis.Semantic proximity Read ↗

Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.Semantic proximity Read ↗

Cytokine gene polymorphisms support diagnostic monitoring of Romanian multiple myeloma patients.Semantic proximity Read ↗

Interleukin-6 gene-174 G/C promoter polymorphism and its association with clinical profile of patients with multiple myeloma.Semantic proximity Read ↗

An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.Semantic proximity Read ↗

The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.